ABOUT CELYAD ONCOLOGY

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor (CAR) T-cell therapies for cancer.

More Info About Celyad ONCOLOGY

Latest News

Celyad Oncology appoints Georges Rawadi as its new CEO

Celyad Oncology reports full year 2022 financial results and recent business highlights

Celyad Oncology to announce full year 2022 financial results and host conference call

Celyad Oncology announces non-cash impairment

Letter to Shareholders

Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Celyad Oncology Provides Strategic Update

Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Novel CAR T-cell Immunotherapies

Advancing both allogeneic and autologous CAR T-cell therapy candidates for the treatment of cancer

View Pipeline

Celyad Oncology @celyadsa ·

18h

We are so pleased to announce that @CelyadSA has appointed Georges Rawadi as its new CEO!
Georges has over 20 years of experience in pharma/biotech, but also knows Celyad quite well as he spent four years with us as VP BD & IP.
See our PR here: https://celyad.com/?p=8060

Twitter 1639152005221416961

Celyad Oncology @celyadsa ·

23 Mar

Today we report full year 2022 financial results and recent business highlights. Check our press release here: https://celyad.com/?p=8052. Don't forget to join us for our conference call at 1 pm CET /8 am ET! $CYAD

Twitter 1639031756186681344

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.